Atrium Therapeutics, Inc. Common Stock (RNA) valuation · rev $18.8M
Atrium Therapeutics, Inc. Common Stock (RNA) rev $18.8M.
| Metric | Value |
|---|---|
| Market cap | $217.5M |
| Revenue | $18.8M |
| P/S | 11.6 |
| P/B | 0.9 |
RNA valuation FAQ
What is RNA's market cap?
Atrium Therapeutics, Inc. Common Stock (RNA) market cap is $217.5M on the latest cached fundamentals snapshot.
What is RNA's latest revenue?
Latest cached Atrium Therapeutics, Inc. Common Stock (RNA) revenue was $18.8M. Statements: https://lician.com/financials/rna
What is RNA's price-to-sales ratio?
Atrium Therapeutics, Inc. Common Stock (RNA) price-to-sales (P/S) is 11.6, cached market cap $217.5M divided by revenue $18.8M.
What is RNA's price-to-book ratio?
Atrium Therapeutics, Inc. Common Stock (RNA) price-to-book (P/B) is 0.9 on the latest cached fundamentals snapshot.
How many RNA valuation scalars are listed on this page?
This page lists 4 cached valuation scalars for Atrium Therapeutics, Inc. Common Stock (RNA): Market cap, Revenue, P/S, and P/B.
Where is RNA valuation listed?
Cached valuation multiples for Atrium Therapeutics, Inc. Common Stock (RNA) are listed at https://lician.com/valuation/rna.
Not investment advice. Cached rows, not a live tape.